Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Long non-coding RNAs (lncRNAs) are a class of biomarkers of crescent interest in the hematologic and oncologic field. They do not encode proteins and can alter gene expression by acting on different steps of regulation, including DNA methylation and chromatin structure. Recent data identified recurrent somatic alterations in genes involved in DNA methylation and post-translational histone modifications in T-ALL, suggesting that epigenetic homeostasis is critically required in restraining tumor development in the T-cell lineage. Further, recent studies showed that the expression levels of specific lncRNAs correlate with the prognosis of patients with Acute Lymphoblastic Leukemia of T-cells (T-ALL). The objectives of this research project are to identify T-ALL-specific lncRNAs to be used as new diagnostic and prognostic biomarkers of disease and to explore their role on chromatin reorganization and transcriptional regulation that may lead to the onset and progression of T-ALL.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with a diagnosis of T-ALL 1-18 years aged of both sexes; - Presence of leukemic cells in peripheral blood of recruited patients. Who Should NOT Join This Trial: - Patients who refuse to participate in the study; - Patients not falling in the age group mentioned above Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with a diagnosis of T-ALL 1-18 years aged of both sexes; * Presence of leukemic cells in peripheral blood of recruited patients. Exclusion Criteria: * Patients who refuse to participate in the study; * Patients not falling in the age group mentioned above

Treatments Being Tested

DIAGNOSTIC_TEST

lncRNA signature analyses

Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.

Locations (1)

Irccs Synlab Sdn
Naples, Italy